Sorafenib versus observation following surgery for metastatic kidney cancer
A potential treatment for a selected group of patients with [...]
Potential kidney cancer test in development
A Swedish biotechnology company, Elypta, has recently been awarded an [...]
High levels of distress among people with kidney cancer
A recent study published in BJU International reports high levels of [...]
ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance
Results from the latest adjuvant study with a vascular endothelial [...]
Adjuvant sunitinib declined by European Medicines Agency committee
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer
The US Food and Drug Administration (FDA) has approved sunitinib [...]
Researchers discover the mechanism that causes kidney cancer to recur
New research published in the journal Nature Communications this month has identified [...]
Relapse of RCC can be possible years after initial treatment
A recent study published in Oncology Times by a group [...]
